Aplace tablets 100 mg for gastritis and ulcer (troxipide, Troxip, Defensa, Shuqi)
Product Code :
Availability : 12
General information on Japanese Aplace tablets 100 mg for gastritis and ulcer (troxipide, Troxip, Defensa, Shuqi)
Package details: 100 tablets
Manufacturer: Kyorin Pharmaceutical Co. Ltd., Japan
Active ingredients: troxipide (chemical formula C15H22N2O4)
Medical effect: Aplace tablets are effective for the treatment of gastritis and gastric ulcer.
Contraindications and precautions: do not use for pregnant or breastfeeding women. If an allergic reaction occurs, stop using the medicine and consult with your doctor. If you’re taking any other medication or receiving any other treatment, you have to consult with your doctor before use.
Dosage and administration: for adults: take 1 tablet (100 mg of troxipide) at a time, 3 times a day after meals. The doctor in charge may adjust the dosage according to patient’s age and symptoms.
How effective are Aplace tablets 100 mg from Japan for gastritis and ulcer (troxipide, Troxip, Defensa, Shuqi)?
Aplace tablets contain troxipide, a systemic gastric cytoprotective agent. While most of other gastroprotective compounds inhibit acid secretion or neutralize the acid, troxipide works in a different way. Troxipide provides the following effects:
- increases the content of glucosamine and collagen in gastric mucosa,
- increases the amount of mucopolysaccharides in gastric mucosa,
- stimulates cytoprotective prostaglandins,
- enhances epithelial restitution and mucosal healing.
Also, Aplace tablets suppress the gastric inflammation by inhibiting proinflammatory mediators.
Who should use Aplace tablets 100 mg from Japan?
Aplace tablets are effective for the treatment of gastritis and gastric ulcer. Studies showed that treatment course of 12 weeks with troxipide allows to reach an overall improvement of 86.6% and 93.3% in patients with gastric ulcer and duodenal ulcer respectively (Hyeoyun et al. Peptic ulcers for the clinical effectiveness of Troxipide. Latest Med. 1989; 32 (3): 125-31).